Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M91,479Revenue (TTM) $M37,472Net Margin (%)1.1Altman Z-Score1.1
Enterprise Value $M113,140EPS (TTM) $0.1Operating Margin %6.6Piotroski F-Score4
P/E(ttm)242Beneish M-Score-2.7Pre-tax Margin (%)4.1Higher ROA y-yN
Price/Book51910-y EBITDA Growth Rate %1.7Quick Ratio0.7Cash flow > EarningsY
Price/Sales2.75-y EBITDA Growth Rate %7.6Current Ratio1.0Lower Leverage y-yY
Price/Free Cash Flow26.0y-y EBITDA Growth Rate %-76.5ROA % (ttm)0.5Higher Current Ratio y-yN
Dividend Yield %5.6PEG32.0ROE % (ttm)10.7Less Shares Outstanding y-yN
Payout Ratio %1,373Shares Outstanding M2,436ROIC % (ttm)5.0Gross Margin Increase y-yN

Gurus Latest Trades with GSK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GSKKahn Brothers 2016-09-30 Add1.98%$42.5 - $45.49
($43.86)
$ 37.55-14%Add 66.18%632,040
GSKCharles Brandes 2016-09-30 Reduce-0.46%$42.5 - $45.49
($43.86)
$ 37.55-14%Reduce -16.54%3,525,668
GSKNWQ Managers 2016-09-30 Add0.37%$42.5 - $45.49
($43.86)
$ 37.55-14%Add 28.09%2,658,155
GSKHOTCHKIS & WILEY 2016-09-30 Reduce-0.05%$42.5 - $45.49
($43.86)
$ 37.55-14%Reduce -3.42%8,150,402
GSKKen Fisher 2016-09-30 Add0.01%$42.5 - $45.49
($43.86)
$ 37.55-14%Add 1.11%11,861,172
GSKBarrow, Hanley, Mewhinney & Strauss 2016-09-30 Reduce$42.5 - $45.49
($43.86)
$ 37.55-14%Reduce -6.59%235,200
GSKDodge & Cox 2016-09-30 Reduce$42.5 - $45.49
($43.86)
$ 37.55-14%Reduce -5.20%41,962
GSKJoel Greenblatt 2016-09-30 Reduce$42.5 - $45.49
($43.86)
$ 37.55-14%Reduce -2.22%25,284
GSKTweedy Browne 2016-09-30 Reduce$42.5 - $45.49
($43.86)
$ 37.55-14%Reduce -1.41%114,844
GSKKahn Brothers 2016-06-30 Add2.08%$40.04 - $43.47
($42.12)
$ 37.55-11%Add 188.24%380,335
GSKNWQ Managers 2016-06-30 Add1.17%$40.04 - $43.47
($42.12)
$ 37.55-11%Add 316.61%2,075,187
GSKCharles Brandes 2016-06-30 Reduce-0.14%$40.04 - $43.47
($42.12)
$ 37.55-11%Reduce -5.59%4,224,506
GSKHOTCHKIS & WILEY 2016-06-30 Reduce-0.08%$40.04 - $43.47
($42.12)
$ 37.55-11%Reduce -5.34%8,439,389
GSKKen Fisher 2016-06-30 Add0.01%$40.04 - $43.47
($42.12)
$ 37.55-11%Add 0.63%11,730,875
GSKJohn Rogers 2016-06-30 Add0.01%$40.04 - $43.47
($42.12)
$ 37.55-11%Add 1.57%1,607,697
GSKJoel Greenblatt 2016-06-30 Reduce-0.01%$40.04 - $43.47
($42.12)
$ 37.55-11%Reduce -49.63%25,857
GSKTweedy Browne 2016-06-30 Add$40.04 - $43.47
($42.12)
$ 37.55-11%Add 0.36%116,491
GSKDodge & Cox 2016-06-30 Reduce$40.04 - $43.47
($42.12)
$ 37.55-11%Reduce -45.53%44,262
GSKHOTCHKIS & WILEY 2016-03-31 Reduce-0.52%$38.54 - $42.05
($39.84)
$ 37.55-6%Reduce -26.34%8,915,323
GSKKahn Brothers 2016-03-31 Add0.36%$38.54 - $42.05
($39.84)
$ 37.55-6%Add 55.97%131,950
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GSK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


GSK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLCFormer 10% Owner 2015-02-23Sell503,150$2270.68view
GLAXOSMITHKLINE PLC10% Owner 2014-12-18Sell50,000$21.1477.63view
GLAXOSMITHKLINE PLCFormer 10% Owner (1) 2014-10-27Sell11,315,825$5.29609.83view
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$12212.92view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$14168.21view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$12212.92view

Press Releases about GSK :

Quarterly/Annual Reports about GSK:

    News about GSK:

    Articles On GuruFocus.com
    Jeff Auxier Curbs Multiple Positions in 3rd Quarter Dec 01 2016 
    Tweedy Browne Fund Investment Adviser's Semi-Annual Letter to Shareholders Nov 28 2016 
    6 Worthy Dividend Stocks Down 10% or More Nov 22 2016 
    Kahn Brothers Adds to 4 Holdings in 3rd Quarter Nov 02 2016 
    Tweedy Browne Adds to 5 Holdings, Trims 2 Others in 3rd Quarter Oct 11 2016 
    Examine Cognizant's Recent Developments Closely Oct 06 2016 
    Novartis Is Surviving Oct 03 2016 
    Strong Revenue Points to Gains at GlaxoSmithKline Oct 01 2016 
    Ariel Funds Comments on GlaxoSmithKline plc Sep 28 2016 
    John Rogers' Ariel Global Fund 2nd Quarter Commentary Sep 28 2016 

    More From Other Websites
    Asset Sales, New Projects Fuel 6.7% Yield Dec 07 2016
    Pfizer Takes $106 Million Fine From U.K. for Price Hike of Epilepsy Drug Dec 07 2016
    Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016
    GSK insider Waterhouse to head drugmaker's HIV unit ViiV Dec 05 2016
    GSK insider Waterhouse to head drugmaker's HIV unit ViiV Dec 05 2016
    Better buy: GlaxoSmithKline plc vs Shire plc Dec 05 2016
    Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study Dec 05 2016
    What Smart Money Thinks About GlaxoSmithKline plc (ADR) (GSK) Dec 04 2016
    How to Buy GlaxoSmithKline at a 15% Discount Dec 02 2016
    GlaxoSmithKline PLC (ADR) (GSK) Wins Approval Of Its Asthma Drug Nucala Dec 02 2016
    Glaxo and Innoviva Get Positive News (GSK, INVA) Dec 02 2016
    GSK Files Regulatory Submission in European Union for Once-Daily Closed Triple Combination Therapy... Dec 02 2016
    GSK Files Regulatory Submission in European Union for Once-Daily Closed Triple Combination Therapy... Dec 02 2016
    Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use in Patients with COPD Dec 02 2016
    Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use in Patients with COPD Dec 02 2016
    Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use in Patients with COPD Dec 02 2016
    Director/PDMR Shareholding Dec 01 2016
    Total Voting Rights Dec 01 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)